RBC Capital analyst Sean Dodge lowered the firm’s price target on Teladoc to $25 from $30 but keeps an Outperform rating on the shares. The company’s Q4 update was mixed with EBITDA that was better than expected but a longer-range revenue growth outlook of low-mid single digts that will likely be viewed as “disappointing” against the 7% growth rate implied in consensus, the analyst tells investors in a research note. The firm is rolling forward its multiple with assumed 11-times expected 2025 EBITDA estimate vs. 15-times expected 2024 EBITDA view prior, RBC added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TDOC:
- Teladoc Inc. Earnings Update: Did it Beat Estimate Forecasts?
- Teladoc (NYSE:TDOC) Delivers Mixed Q4, Stock Drops On Downbeat Outlook
- Teladoc Health Reports Fourth Quarter and Full Year 2023 Results
- Options Volatility and Implied Earnings Moves Today, February 20, 2024
- Teladoc Health Provides Updated Start Time for Fourth Quarter 2023 Earnings Call on February 20, 2024